ATE189957T1 - Verwendung von nadph-oxidase-inhibitoren zur herstellung eines arzneimittels zur vorbeugung der arteriosklerose - Google Patents

Verwendung von nadph-oxidase-inhibitoren zur herstellung eines arzneimittels zur vorbeugung der arteriosklerose

Info

Publication number
ATE189957T1
ATE189957T1 AT96940912T AT96940912T ATE189957T1 AT E189957 T1 ATE189957 T1 AT E189957T1 AT 96940912 T AT96940912 T AT 96940912T AT 96940912 T AT96940912 T AT 96940912T AT E189957 T1 ATE189957 T1 AT E189957T1
Authority
AT
Austria
Prior art keywords
production
nadph oxidase
medicinal product
oxidase inhibitors
preventing arteriosclerosis
Prior art date
Application number
AT96940912T
Other languages
English (en)
Inventor
James A Holland
David K Johnson
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Application granted granted Critical
Publication of ATE189957T1 publication Critical patent/ATE189957T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
AT96940912T 1995-11-27 1996-11-27 Verwendung von nadph-oxidase-inhibitoren zur herstellung eines arzneimittels zur vorbeugung der arteriosklerose ATE189957T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,767 US5763496A (en) 1995-11-27 1995-11-27 Prevention of atherosclerosis using NADPH oxidase inhibitors
PCT/US1996/019053 WO1997019679A2 (en) 1995-11-27 1996-11-27 Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis

Publications (1)

Publication Number Publication Date
ATE189957T1 true ATE189957T1 (de) 2000-03-15

Family

ID=24247689

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96940912T ATE189957T1 (de) 1995-11-27 1996-11-27 Verwendung von nadph-oxidase-inhibitoren zur herstellung eines arzneimittels zur vorbeugung der arteriosklerose

Country Status (10)

Country Link
US (2) US5763496A (de)
EP (2) EP0861070B1 (de)
JP (2) JPH11507946A (de)
AT (1) ATE189957T1 (de)
AU (1) AU1085997A (de)
CA (1) CA2238098C (de)
DE (1) DE69606882T2 (de)
ES (1) ES2144792T3 (de)
GR (1) GR3033067T3 (de)
WO (1) WO1997019679A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012539A1 (en) * 1997-09-10 1999-03-18 The Johns Hopkins University School Of Medicine The use of an nadph-oxidase inhibitor in the treatment of reperfusion injury
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
AU782564B2 (en) * 2000-02-09 2005-08-11 Paul A Sneed Treatment of fibromyalgia with Ubiquinone 10 and succinic acid
US20020022022A1 (en) * 2000-05-19 2002-02-21 Yi Shi Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors
US6492429B1 (en) * 2000-07-10 2002-12-10 N.V. Nutricia Composition for the treatment of osteoarthritis
WO2002030453A1 (en) * 2000-10-12 2002-04-18 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
WO2002053161A1 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
DE10104825A1 (de) * 2001-02-01 2002-08-08 Florian Lang Screening von Antimalariamitteln
US7202030B2 (en) * 2001-11-01 2007-04-10 Rensselaer Polytechnic Institute Solid-phase array-based biocatalytic transformations
WO2003055473A1 (en) * 2001-12-21 2003-07-10 Charlotte Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Regulation of nad(p)h oxidase growth and transcription in melanoma cells
US6949586B2 (en) * 2002-02-11 2005-09-27 Council Of Scientific Research Synergistic composition of trans-tetracos-15-enoic acid and Apocynin and method of treatment for hepatotoxicity
AU2003224549A1 (en) * 2002-04-17 2003-10-27 Biovitrum Ab Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
PT1509618E (pt) * 2002-05-13 2008-12-02 Arexis Ab Condições autoimunes e deficiências de nadph-oxidase
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
WO2004069201A2 (en) * 2003-02-03 2004-08-19 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
CN1774243A (zh) * 2003-02-28 2006-05-17 霍华德弗洛里实验生理及医药学院 治疗组合物
JPWO2004096198A1 (ja) * 2003-05-02 2006-07-13 タカラバイオ株式会社 治療剤
WO2005103297A1 (en) * 2004-03-31 2005-11-03 Georgetown University METHODS AND COMPOSITIONS RELATED TO MODULATION OF p22phox
EP1602926A1 (de) 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
US20070254900A1 (en) * 2004-08-11 2007-11-01 Kassab Ghassan S Treatments for Congestive Heart Failure
US8569374B2 (en) 2004-09-16 2013-10-29 The Trustees Of The University Of Pennsylvania NADPH oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US20080051451A1 (en) * 2006-03-15 2008-02-28 Marcel Linschoten Autoimmune conditions and NADPH oxidase defects
EP2002835A1 (de) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolopyridinderivate als NADPH-Oxidasehemmer
EP2520561B1 (de) 2007-06-08 2016-02-10 MannKind Corporation IRE-1a-Inhibitoren
KR100989093B1 (ko) * 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
EP3578177A1 (de) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzungen mit eicosapentaensäure und nikotinsäure und verfahren zur verwendung davon
EP2165707A1 (de) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolopyridinderivate als NADPH-Oxidasehemmer
EP2166009A1 (de) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolopyridinderivate als NADPH-Oxidasehemmer
EP2166010A1 (de) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolopyridinderivate als NADPH-Oxidasehemmer
NZ627238A (en) 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
NZ789295A (en) 2009-04-29 2024-02-23 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN114053258A (zh) 2009-06-15 2022-02-18 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
EP2305679A1 (de) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazolindionderivate als NADPH-Oxidasehemmer
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
WO2013136277A1 (en) 2012-03-13 2013-09-19 Unimark Remedies Ltd. Pharmaceutical compositions for treatment of cardiovascular diseases
US20140080850A1 (en) * 2012-06-05 2014-03-20 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
JP2015522029A (ja) 2012-06-29 2015-08-03 アマリン ファーマシューティカルス アイルランド リミテッド スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
WO2014183184A1 (en) * 2013-05-14 2014-11-20 University Of Prince Edward Island Compositions and methods for treating cardiometabolic diseases and disorders
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3034500A1 (de) 2014-12-17 2016-06-22 Genkyotex Sa Amidothiazolderivate als NADPH-Oxidasehemmer
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3506895A4 (de) 2016-09-01 2020-04-15 JDS Therapeutics, LLC Magnesiumbiotinatzusammensetzungen und verfahren zur verwendung
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN112218630A (zh) 2018-09-24 2021-01-12 阿马里纳药物爱尔兰有限公司 降低受试者的心血管事件的风险的方法
JP2022515314A (ja) 2018-11-02 2022-02-18 ニュートリション・２１，エルエルシー イノシトール安定化アルギニンケイ酸塩複合体及びイノシトールを含有するビデオゲームプレーヤーの認知機能を改善するための組成物
EP4076413A1 (de) 2019-12-16 2022-10-26 Nutrition 21, LLC Verfahren zur herstellung von arginin-silikat-komplexen
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593966A (en) * 1989-03-31 1997-01-14 The United States Of America As Represented By The Department Of Health And Human Services Peptide derivatives of cytochrome b558 and their use as medicaments
DE4109627A1 (de) * 1991-03-23 1992-09-24 Boehringer Mannheim Gmbh Neue phenolether, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
GB9200623D0 (en) * 1992-01-13 1992-03-11 Bayer Ag Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
JPH06135880A (ja) * 1992-10-30 1994-05-17 Kanebo Ltd 活性酸素消去剤
JP3023254B2 (ja) * 1992-11-05 2000-03-21 鐘紡株式会社 メラニン生成抑制剤
JPH06227977A (ja) * 1993-02-01 1994-08-16 Suntory Ltd 活性酸素消去剤
AU1095695A (en) * 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
JPH07165575A (ja) * 1993-12-08 1995-06-27 Nippon Oil & Fats Co Ltd ヒドロキノン誘導体
JP2774063B2 (ja) * 1993-12-24 1998-07-09 鐘紡株式会社 抗酸化組成物

Also Published As

Publication number Publication date
EP0861070A2 (de) 1998-09-02
DE69606882D1 (de) 2000-04-06
ES2144792T3 (es) 2000-06-16
US5902831A (en) 1999-05-11
WO1997019679A3 (en) 1997-08-28
EP0914821A3 (de) 2000-04-26
DE69606882T2 (de) 2000-08-17
EP0861070B1 (de) 2000-03-01
JPH11507946A (ja) 1999-07-13
AU1085997A (en) 1997-06-19
WO1997019679A2 (en) 1997-06-05
JP2003176224A (ja) 2003-06-24
US5763496A (en) 1998-06-09
GR3033067T3 (en) 2000-08-31
CA2238098C (en) 2001-01-30
EP0914821A2 (de) 1999-05-12
CA2238098A1 (en) 1997-06-05

Similar Documents

Publication Publication Date Title
ATE189957T1 (de) Verwendung von nadph-oxidase-inhibitoren zur herstellung eines arzneimittels zur vorbeugung der arteriosklerose
ATE442851T1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
DE69736183D1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DK0955880T3 (da) Apparat til behandling af hjertearytmi uden noget diskret mål
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
DE69013119D1 (de) Verfahren zum Herstellen einer sterilen Flüssigkeit für medizinischen Gebrauch oder einer ähnlichen physiologisch akzeptablen sterilen Flüssigkeit.
ATE145136T1 (de) Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
DE58903917D1 (de) Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels sowie daraus hergestelltes arzneimittel und verfahren zu seiner herstellung.
DE69620786T2 (de) Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie
DE3686097D1 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE3578374D1 (de) Verwendung von chinolonen fuer die herstellung eines arzneimittels zur behandlung von herzerkrankungen.
DE69915848D1 (de) Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
DE3873210D1 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
ATE222762T1 (de) 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus
DE3873188D1 (de) Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen.
NO890801D0 (no) Fremgangsmaate for fremstilling av lysyloxydaseinhibitorer.
EP0857781A3 (de) Promotor des humanen Endoglingens sowie seine Verwendung
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE307587T1 (de) Verwendung von thiaminen zur herstellung eines arzneimittels zur prophylaxe und zur therapie der diabetischen retinopathie und der diabetischen nephropathie
ATE263565T1 (de) Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten
ES2179867T3 (es) Entrecruzamientos de piridinolina como marcadores de actividad de enfermedad periodontal o peri-implante.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee